These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37217115)

  • 1. Risk factors for recurrent healthcare-facility associated Clostridioides difficile infection in a Swedish setting.
    Karp J; Edman-Wallér J; Toepfer M; Jacobsson G
    Anaerobe; 2023 Jun; 81():102738. PubMed ID: 37217115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clostridioides difficile incidence related to in-hospital cephalosporin use: a tale of two highly comparable hospitals.
    Karp J; Edman-Wallér J; Toepfer M; Lundqvist A; Jacobsson G
    J Antimicrob Chemother; 2019 Jan; 74(1):182-189. PubMed ID: 30358837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter study of Clostridium difficile infection rates from 2000 to 2006.
    Dubberke ER; Butler AM; Yokoe DS; Mayer J; Hota B; Mangino JE; Khan YM; Popovich KJ; Fraser VJ
    Infect Control Hosp Epidemiol; 2010 Oct; 31(10):1030-7. PubMed ID: 20695799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burden of Clostridioides difficile infection (CDI) - a systematic review of the epidemiology of primary and recurrent CDI.
    Finn E; Andersson FL; Madin-Warburton M
    BMC Infect Dis; 2021 May; 21(1):456. PubMed ID: 34016040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic Exposure and Risk for Hospital-Associated Clostridioides difficile Infection.
    Webb BJ; Subramanian A; Lopansri B; Goodman B; Jones PB; Ferraro J; Stenehjem E; Brown SM
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964789
    [No Abstract]   [Full Text] [Related]  

  • 6. Incidence of and risk factors for recurrent Clostridioidesdifficile infection in Japan using a claims database: A retrospective cohort study.
    Mikamo H; Kondo T; Okuyama K; Marcella SW; Ruzicka DJ
    Anaerobe; 2020 Feb; 61():102139. PubMed ID: 31830597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotics and healthcare facility-associated Clostridioides difficile infection: systematic review and meta-analysis 2020 update.
    Slimings C; Riley TV
    J Antimicrob Chemother; 2021 Jun; 76(7):1676-1688. PubMed ID: 33787887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare associated
    Šuljagić V; Milenković B; Perić A; Jovanović D; Begović-Kuprešanin V; Starčević S; Tomić A; Vezmar Kovačević S; Dragojević-Simić V
    Libyan J Med; 2020 Dec; 15(1):1708639. PubMed ID: 31905110
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure.
    Johnson SW; Brown SV; Priest DH
    Clin Infect Dis; 2020 Aug; 71(5):1133-1139. PubMed ID: 31560051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.
    Kimura T; Snijder R; Sugitani T
    J Infect Chemother; 2019 Aug; 25(8):615-620. PubMed ID: 30987950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clostridioides difficile infection: Incidence and risk factors in a tertiary care facility in Riyadh, Saudi Arabia.
    Alzouby S; Baig K; Alrabiah F; Shibl A; Al-Nakhli D; Senok AC
    J Infect Public Health; 2020 Jul; 13(7):1012-1017. PubMed ID: 31831398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare-associated
    Manea E; Jipa R; Milea A; Roman A; Neagu G; Hristea A
    Rom J Intern Med; 2021 Dec; 59(4):409-415. PubMed ID: 34053203
    [No Abstract]   [Full Text] [Related]  

  • 13. Retrospective study of the efficacy and safety of metronidazole and vancomycin for Clostridioides difficile infection.
    Misawa K; Iketani O; Enoki Y; Taguchi K; Uno S; Uwamino Y; Hasegawa N; Matsumoto K
    J Infect Chemother; 2021 Oct; 27(10):1407-1412. PubMed ID: 34023223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter study of the impact of community-onset Clostridium difficile infection on surveillance for C. difficile infection.
    Dubberke ER; Butler AM; Hota B; Khan YM; Mangino JE; Mayer J; Popovich KJ; Stevenson KB; Yokoe DS; McDonald LC; Jernigan J; Fraser VJ;
    Infect Control Hosp Epidemiol; 2009 Jun; 30(6):518-25. PubMed ID: 19419269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of Clostridioides difficile infections treated in a Swiss tertiary care hospital: an observational study.
    Haubitz S; Bartlomé N; Bucheli Laffer E; Spelters C; Fankhauser H; Fux CA
    Swiss Med Wkly; 2020 Jan; 150():w20173. PubMed ID: 31940431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing risk factors, mortality, and healthcare utilization associated with Clostridioides difficile infection in four Latin American countries.
    Yu H; Flaster N; Casanello AL; Curcio D
    Braz J Infect Dis; 2021; 25(1):101040. PubMed ID: 33290727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic exposure and the risk of hospital-acquired diarrhoea and Clostridioides difficile infection: a cohort study.
    Schechner V; Fallach N; Braun T; Temkin E; Carmeli Y
    J Antimicrob Chemother; 2021 Jul; 76(8):2182-2185. PubMed ID: 33969419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
    Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
    Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Effect of Saccharomyces boulardii Primary Prevention on Risk of Hospital-onset Clostridioides difficile Infection in Hospitalized Patients Administered Antibiotics Frequently Associated With C. difficile Infection.
    Wombwell E; Patterson ME; Bransteitter B; Gillen LR
    Clin Infect Dis; 2021 Nov; 73(9):e2512-e2518. PubMed ID: 32575126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.